MGMarine Gilles

Marine Gilles

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marine Gilles has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Increasing plant protein sources in the diet modulates gut microbiota and tryptophan metabolism in men at cardiometabolic risk

    by Gaïa Lépine, Anne-Marie Davila, Gwendal Cueff, Gisèle Pickering, Farid Ichou, Caroline Perreau, Catherine Lefranc-Millot, Marine Gilles, Florence Thirion, François Mariotti, et al.

    Western dietary patterns, characterized by high intakes of red and processed meat, saturated fat, and refined carbohydrates, contribute substantially to the global burden of cardiometabolic disease...


  • Open Access

    Short-chain fructo-oligosaccharides modulate gut microbiota composition and metabolism: dose–response assessment in an ex vivo gut model

    by Christelle Bressuire, Florence Thirion, Laura Chiaravano, Serigne Inssa Ngom, Romane Marion, Marine Gilles, Benoît Quinquis, Elliot Mathieu, Magali Berland, Hervé M. Blottière, et al.

    Short-chain fructo-oligosaccharides (scFOS) are prebiotic fiber rapidly fermented in the colon and known to stimulate beneficial bacteria, such as Bifidobacterium spp. and Lactobacillaceae. While their overall effects on the gut microbiota are established, the dose–response relationship remained only partially characterized. This study aimed to determine the minimum effective dose of scFOS required to modulate gut microbiota composition and functions. An ex vivo chemostat model was used to simulate colonic fermentation with different doses of scFOS (1 to 10 g/d). Microbiota composition and metabolic activity were assessed by qPCR, short-chain fatty acid (SCFA) quantification, and shotgun metagenomics. An increase in scFOS dose led to higher SCFA levels, particularly acetate and butyrate, along with a modification in microbial composition, with a minimum significant effective dose of 2.5 g/d. Significant increase in Bifidobacterium adolescentis, Anaerostipes hadrus, and Clostridium innocuum was observed at the same dose. Functional analysis revealed an enrichment of GH32 genes in the pangenomes of species positively impacted by scFOS. These findings demonstrate that low doses of scFOS can effectively modulate the gut microbiota and enhance SCFA production, supporting their use in dietary interventions aimed at improving intestinal health.

  • Open Access

    Microbiome signature of Parkinson disease in healthy and genetically at-risk individuals

    by Elisa Menozzi, Victoria Meslier, Yani Ren, Mallia Geiger, Jane Macnaughtan, Micol Avenali, Marine Gilles, Caterina Galandra, Pierfrancesco Mitrotti, Luca Gallo, et al.

    Summary: Parkinson disease (PD) is a major cause of disability with significant personal and system financial implications 1,2 . GBA1 variants are the commonest genetic risk factor for PD and increase the risk up to 30-fold 3,4 . Why only ∼20% of GBA1 variant carriers develop PD remains unknown. Here, by combining clinical and faecal metagenomics data from PD individuals carrying or not GBA1 variants, carriers of GBA1 variants not manifesting PD symptoms (GBA-NMC) and healthy controls, and using an innovative microbiome analysis, we show that a large component of the gut microbiome evolves from healthy across GBA-NMC towards PD and is strongly correlated with disease progression in patients, and prodromal symptoms suggestive of future development of PD in GBA-NMC. By using species altered in PD and GBA-NMC, we detect healthy individuals with the strongest prodromal PD clinical profile. These findings indicate that gut microbiome alterations can identify individuals with GBA1 variants most prone to develop PD and individuals in the general population that may be progressing towards PD. Healthy nutrition mitigates microbiome alterations associated with disease severity, suggesting that it could modify disease progression in PD patients and decrease the risk of disease development in healthy individuals including those with GBA1 variants.